Formulation for the treatment of obesity

ABSTRACT

The present invention refers to a formulation for a slimming treatment comprising in certain quantities: hypothalamus powder, hypophysis powder, thyroid powder, suprarenal cortex powder and pancreas powder, and other polyglandular opotherapic extracts such as extract of ovary or testicle; said slimming treatment being evaluated and optimised thanks to an exponential mathematical model which models the accumulated weight loss of a patient by means of a differentiation and separation of the slimming effect due to the set of factors depending on the applied slimming treatment and, on the other hand, of the slimming effect due to the set of factors depending on the typology of the patient trying to slim.

FIELD OF THE TECHNIQUES

[0001] The present invention falls within the field of treatments forobesity and overweight.

STATE OF THE ART PRIOR TO THE INVENTION

[0002] Obesity is a multiple aetiology problem, in the genesis of whichthere are many factors intervening in an isolated form or, very muchmore frequently, in a combined form. The involvement of so many factorsis what sometimes makes it impossible to predict the result that mightbe obtained by means of a slimming method with a particular patient.

[0003] Moreover, surprisingly, these uncertainties contrast sharply withthe profound knowledge currently had of the most intimate physiologicaland biochemical mechanisms intervening in the physiopathology ofobesity. Thus, well known are the digestive and intestinal absorptionmechanisms, the mechanisms of insulin regulation, the mechanisms ofglucemia regulation (hepatic, muscular and central), the physiology andhistology of adipose tissue, thyroid physiology and pathology, thephysiology and pathology of the hypophysis, etc. It can be said that afair amount is known about the phenomena inherent to glandular, tissueand cellular physiology and pathology, involved in disturbances to theadipose tissue and obesity.

[0004] A fundamental work on the absorption mechanism of oligopeptidesand amino acids is: D. A. Silk Progress report. Peptide absorption inman, Gut, 1974, 15 494-501. This work reveals that there exist twoessential mechanisms in peptide absorption: on the one hand thehydrolysis of peptides by brush border enzymes with the consequentabsorption of amino acids released by means of specific amino acidtransport systems, and on the other hand the absorption of peptides bymechanisms independent of the specific entrance of each amino acid,followed by intracellular hydrolysis.

[0005] With regard to amino acid and peptide absorption, K. E. Webb,Jr., Amino acid and peptide absorption from the gastrointestinal tract,Federation Proceedings Vol 45, no. 8 July 1986, describes that the largequantity of peptide amino acids appearing in portal plasma issurprising, corresponding to more than 70% of the total quantity ofportal plasma amino acids. And it is also observed that, with theexception of cysteine they are all associated with amino acids comingfrom diet. Therefore, if these peptidic amino acids come from diet, thisgreat contribution will be of essential nutritional importance.

[0006] Moreover, in addition to the knowledge of the physiologicalmechanisms stated above, there also exists a wide-ranging knowledge ofthe basis on which many existing slimming formulations are founded andthe principles on which the administration of different substances forslimming purposes are based. It is worth recalling, for example, thatopotherapy, or treatment of insufficiencies, or absence of glands, or oforgans, by means of fresh organs and/or extracts of these organs inliquid or powder form, has its roots at the end of the nineteenthcentury, and there currently exist opotherapic products for any tissueor organ of the body. Opotherapic products are regulated in thepharmacopoeia. An essential work on opotherapy is the doctoral thesis ofJean-Clause Dahan, Les substances d'origine animale utulisées entherapeutique, 1987, Université Paris V René Descartes. It isfurthermore known that the role of the hypothalamus in the organism isessential, and that its most relevant function from the viewpoint ofopotherapy is the regularisation of hyperphagia or exaggerated appetitein obesity (Hypothalamic Hormones (Serono Symposia) Academic Press Inc.London 1975; Une nouvelle chimie du cerveau Martine Allain-Regnault).Opotherapic products of hypothalamus powder have recently been preparedfor different purposes, as contained in “la Revue TRIANGLE: journalSandoz des Sciences Médicales, deuxiéme trimestre 1976, volume XVI,number 2. In the case of its use for the preparation of slimmingformulations, the ventrolateral nuclei or hunger nuclei are eliminatedfrom the hypothalamus. This means that for the preparation of aformulation for a slimming treatment, a natural anorexic is available.

[0007] As potential components of slimming formulations, there existsubstances such as chlorodiazepoxide, diazepam and bumetanide, whichhave been known and used for a long time in hospital practice. Animportant work on bumetanide is that of John A. Owen, Jr. MD. Focus onbumetanide. An extremely potent diuretic with minimal toxicity September1981 Hospital Formulary, 933-935. Another important work onbenzodiazepines is that by Alastair J. J. Wood “Use of benzodiazepinesin anxiety disorders” The New England Journal of Medicine, May 13, 1993.

[0008] By virtue of this knowledge, it is therefore not understood whythe results presently obtained with slimming treatments are sounpredictable. In theory, there are two answers: the first is that thedifferent and profound branches of partial knowledge have not beensufficiently assembled together so far, and the second is that thereexists some other aspect or aspects that are partially unknown or whichhave not been taken sufficiently into account. It can be concluded thatboth those answers are true in part, in other words, on the one hand allthe partial factors have not been assembled properly and, moreover, someof the partial mechanisms have not been taken sufficiently into accountwhen it comes to designing a slimming treatment.

[0009] Nevertheless, in spite of that knowledge of many factors that acton obesity and which therefore determine the result of a treatment forthis condition, there does not exist a complete knowledge of theinterrelation between those factors. For this reason, in many cases itis not known to which types of factors the success or failure of aslimming plan should be attributed, or whether it should be attributedto all of them. So, the result of a treatment against obesity continuesto lie largely in the hands of chance.

[0010] Therefore, there exists a need for a method which, in theappropriate manner and magnitude, would consider all the factorsintervening in obesity in order to overcome the drawbacks mentioned andbe able to guarantee the desired results in its treatment.

BRIEF DESCRIPTION OF THE INVENTION

[0011] The present invention refers to a formulation for a slimmingtreatment comprising at least:

[0012] hypothalamus powder in a quantity between 0.01 and 0.5 mg,

[0013] hypophysis powder in a quantity between 1 mg and 30 mg,

[0014] thyroid powder in a quantity between 10 and 40 mg, and

[0015] suprarenal cortex powder and pancreas powder in a proportion of1:4

[0016] this slimming treatment being evaluated and optimised thanks toan exponential mathematical model which models the accumulated weightloss of a patient by means of a differentiation and separation of theset of factors depending on the applied slimming treatment and of theset of factors depending on the typology of the patient trying to slim.

BRIEF DESCRIPTION OF THE FIGURES

[0017]FIG. 1 is a representation in Cartesian coordinates of the clusterof points corresponding to the accumulated weekly weight loss inrelation to the passing of days.

[0018]FIG. 2 illustrates a generic form of an exponential function bymeans of which it is intended to mathematically model the cluster ofpoints corresponding to the accumulated weekly weight loss, in relationto the passing of days, by means of fitting the constants K₁ and K₂.

[0019]FIG. 3 represents a study of various values of IB (or SlimmingPotential), each of them establishing a different asymptote oraccumulated slimming limit, with IM (or Efficiency Index) remainingconstant.

[0020]FIG. 4 represents a study of various values of IM (or EfficiencyIndex), each of them establishing a different curvature or speed ofaccumulated weight loss, with IB (or Slimming Potential) remainingconstant.

[0021]FIG. 5 shows some factors that influence obesity and its relationwith the components of the formulation of the present invention whichact against the negative effects produced by those factors.

DETAILED DESCRIPTION OF THE INVENTION

[0022] For the production of the mathematical model permitting theformulation for the slimming treatment forming the object of theinvention to be evaluated and optimised, one starts from the fact that,as can be seen in Table I, among the factors that can influence obesity,some (marked with (1)) depend on the typology of the patient, whileothers (marked with (2)) depend on the slimming method used. TABLE IFactors inherent Factors that are external to the organism (1) or of thetreatment (2) heredity dietary habits (eating a lot, eating quickly)length of time of the obesity type of job activity (hyperplasia orhypertrophic) backgrounds of other slimming sedentarism treatmentsnervous typology climatic changes character type of dietary treatmentdegree of stress type of medical treatment backgrounds of surgicaloperations type of psychological treatment menarche (women) othersmenopause (women) others

[0023] This differentiation into aetiological factors (1) and (2)already implies a first and fundamental simplification of the problem.

[0024] On the other hand, one starts from research conducted with 1,800patients, selected and distributed into 9 groups of 200 people each,according to sex, maternity and fertility, degree of stress, and type ofslimming treatment applied (VLCD=Very low calorie diet), as illustratedin Table II: TABLE II GROUPS OF PATIENTS STUDIED 1 men, middle age,normal activity and only subject to VLCD 2 women, fertile age,childless, normal activity and only with VLCD 3 women, with children,normal activity and births without general anaesthetic (VLCD) 4 women,with children, normal activity and births with general anaesthetic(VLCD) 5 women during the menopause (VLCD) 6 women, 10 years after themenopause (VLCD) 7 men, subject to very stressful activity and VLCD 8men, not stressed, subject to VLCD and anorexics 9 men, not stressed,subject to VLCD and ansiolytics

[0025] For each patient, the weight losses achieved in each week oftreatment were recorded up to a total of 12 weeks. These data,represented on Cartesian axes, with the time variable (week) on theabscissa axis and weight loss on the ordinate axis, do not revealanything interesting.

[0026] Nevertheless, when not just the simple weight loss per week, butinstead the weight loss for each week accumulated with the previousweeks is represented on the ordinate axis, then a cluster of pointsresults which, according to the mathematical model followed for thepresent invention, is identified or modelled by means of a curve ofexponential growth, with an attenuated growth and which tendsindefinitely towards an asymptote parallel with the abscissa axis.Therefore, for each patient, the “y” variable represents the accumulatedweight loss per week (stated in kilograms) on the ordinate axis, as afunction of the “x” variable, which represents the time passed with thepatient subject to a certain slimming treatment on the abscissa axis, upto a total of 12 weeks.

[0027] These data are illustrated for a particular case in FIG. 1, wherethe cluster of points can be observed, and in FIG. 2, where a genericform of an exponential function is illustrated, by means of which it isintended to mathematically model that cluster of points, through thefitting of the constants K₁ and K₂.

[0028] These curves obtained representing the accumulated weight losseach week on the ordinate, and the time passed since the start of theslimming treatment on the abscissa correspond mathematically toequations of the type y=K₁·*(1−10^(−K2·X)), in which K₁ and K₂ are twoconstants.

[0029] These types of curve are frequent and habitual in biologicalphenomena such as embryo growth or the growth of bacterial colonies. So,in the case of weight loss there is a phase of quick exponential weightloss, followed by a phase of slower loss until reaching the moment atwhich the weight loss is infinitesimal and finally stops in the zone inwhich the asymptote has been reached.

[0030] Such exponential functions depend on a single variable (x), butalso influenced by two constants: K₁, which expresses the asymptote ormaximum height that the curve can reach, indicating that, no matter howmuch time passes, no additional weight loss will occur beyond thatobtained; and K₂, which expresses the curvature of the curve, in thiscase indicating the speed with which the growth in the first phase takesplace, in other words, the speed with which the weight loss takes place.Each of these constants comprises or expresses a group of factors.Therefore, some factors are included in K₁ and thereby influence themaximum height of the curve, and others are included in K₂ expressingthe speed with which the accumulated weight loss in the first phasegrows. What “y” represents is the number of kilograms of weight lost asthe days of treatment pass.

[0031] By means of studying the 9 groups of 200 patients each, statedabove, and on the basis also of that described in Tables I and II, it isdemonstrated that each of the two constants K₁ and K₂ is associated withone type of the factors that intervene in obesity. On the one hand, ithas been verified that the factors included in K₁ correspond to thefactors inherent to each person, which therefore depend on thecharacteristics of the patient, such as hormone factors, habits, etc.Each person, on account of his or her nature, possesses a maximum limitof weight loss, independent of the time during which the treatment ismaintained. That maximum limit is the asymptote of the particular curveof that patient. No matter how long the treatment is kept up for, thepatient will not be able to lose weight above the value represented byK₁.

[0032] On the other hand, it has been confirmed that a second type offactors depends on the slimming method applied, and these are thefactors encompassed within K₂.

[0033] K₁ therefore encompasses hereditary factors, hormone factors,habits, etc., in other words, factors classified as (1) in Table Iabove.

[0034] On the other hand, the constant K₂ includes those factors whichdepend solely on the sliming method applied, since each method entails agreater or lesser speed of weight loss, depending on its efficacy andcharacteristics, such as type of diet, medication, exercise, etc. Inother words, K₂ encompasses the factors classified as (2) in Table Iabove, among others, which can depend on the treatment. The constant K₂is only affected by the different slimming power of the slimmingtreatment applied, and in the graph it is represented by the degree ofcurvature of the curve; in other words, the speed with which the curveascends to the asymptote.

[0035] The constant K₁ will henceforth be known as Slimming Potentialand be referred to as IB (“body”) and depends exclusively on thecharacteristics of the patient, representing the maximum weight he orshe can lose, no matter what the slimming method used and the length oftime subject to treatment.

[0036] The constant K₂ will henceforth be known as Efficiency Index andbe represented as IM (method), therefore expressing the greater orlesser speed with which a particular patent can achieve the maximumweight loss.

[0037] The curve of accumulated weight loss for each patient cantherefore be represented by the equation:

W=IB·(1−10^(−IM·N))   Equation (1)

[0038] in which W represents the accumulated weight loss by the patient,N is the number of weeks of treatment and IB and IM have the meaningstated above.

[0039] The value of IB can lie between 0 and infinity, since it is themaximum weight loss, so that when IB=0, W coincides with the abscissaaxis, which would mean that the patient would never slim at all. Thissituation corresponds to an extremely thin person for whom no methodcould cause them to slim more. It could also represent the case of aperson who is obese but incapable of slimming. These two situations aremerely theoretical and do not occur in practice. On the other hand, whenIB is infinite, this means that the patient would never stop slimming,in other words, they would never reach their asymptote, something whichalso does not occur in practice.

[0040]FIG. 3 represents a study of various values of IB (each of themestablishing a different accumulated slimming asymptote or limit), withIM remaining constant.

[0041] When IM=0, the weight loss is also nil, and this would mean thatthe method used has an efficacy that is so low that the curve does notrise up from the abscissa axis, no matter how many weeks the treatmentlasts for. This situation could occur in the case of not applying themethod or, more commonly, in the case of total non-compliance of thetreatment by the patient. The final motive for this situation would becomplete inefficacy of the treatment, which does not occur in practice.

[0042] The situation in which IM is infinite likewise lacks any sense.This situation would occur in the case of the treatment being soeffective that the maximum weight loss would be obtained in the firstday of applying the slimming method, which would only be possible bymeans of a liposuction treatment or surgical removal of all the fat inthe body.

[0043]FIG. 4 represents a study of various values of IM (each of themestablishing a different accumulated weight loss curvature or speed),with IB remaining constant.

[0044] In practice, of course, situations occur that correspond tointermediate values, both for IB and for IM.

[0045] Table III presents by way of example a list of data on aparticular patient that can be represented as a cluster of points on theCartesian axes (No. of weeks, accumulated kilos lost) and the results tobe obtained assimilating or modelling that cluster of points to theexponential mathematical model, for a particular patient: TABLE IIIINPUT INFORMATION INFORMATION TO OBTAIN Accumulated Time weight loss(days) (kg/week) 7 3.200 IB + IM = exponential CURVE 14 6.500 21 8.60028 10.700 35 12.450 42 13.880 49 14.930 56 15.610 63 16.030 70 16.360 7716.560 84 16.680

[0046] With the aim of finding the exponential curve defined by IB(asymptote) and IM (curvature) providing the closest possible fit to thegiven cluster of points, the widely known mathematical method of leastsquares is turned to, consisting of finding which values (in this caseof IB and IM) minimise the mean square error of the curve defined by IBand IM in relation to that given cluster of points for each patient inparticular who has followed a specific slimming method.

[0047] Starting from Equation (1), the ordinate of a point (or day) “i”is given by the equation:

W _(i) =IB·(1−10^(−IM·N))   Equation (2)

[0048] (in which N_(i) is the corresponding day and W_(i) is theaccumulated weight loss up to that day).

[0049] The square error (ε) or difference squared between the set ofpoints W_(i) corresponding to Equation (2) and the points W_(fi)corresponding to the real data recorded by the patients will thereforebe: $\begin{matrix}{ɛ = {{\sum\limits_{i = 1}^{n}\quad \left( {W_{i} - W_{fi}} \right)^{2}} = {\sum\limits_{i = 1}^{n}\quad \left( {{{IB} \cdot \left( {1 - {10^{{- {IM}} \cdot N}i}} \right)} - W_{fi}} \right)^{2}}}} & {{Equation}\quad (3)}\end{matrix}$

[0050] (“n” being the number of days (points) to consider and W_(fi) thereliable value of accumulated weight loss on day “i”, calculated on thebasis of the arithmetic mean of the 200 values corresponding to 200people of a single group who accord with one of the 9 typologies ofpeople mentioned in Table II).

[0051] In order to minimise the square error (ε): the first partialderivative of ε (Equation (3)) with respect to IB is set equal to zeroand an equation is obtained with respect to IB with the minimum error ofadaptation to the theoretical curve postulated for the cluster of pointsresulting from the experimental data:${{\left. {\frac{\partial ɛ}{\partial{IB}} = {2 \cdot {\sum\limits_{i = 1}^{n}\quad \left\{ {{{IB} \cdot \left( {1 - {10^{{- {IM}} \cdot N}i}} \right)} - W_{fi}} \right)}}} \right\} \cdot \left( {1 - {10^{{- {IM}} \cdot N}i}} \right)} = 0};$

[0052] The value of IB being able to be found as a function of IM fromthe above equation:${IB} = \frac{\sum\limits_{i = 1}^{n}\quad {W_{fi} \cdot \left( {1 - {10^{{- {IM}} \cdot N}i}} \right)}}{\sum\limits_{i = 1}^{n}\quad \left( {1 - {10^{{- {IM}} \cdot N}i}} \right)^{2}}$

[0053] Similarly, and with the same aim of minimising the square error(ε): the first partial derivative of ε (Equation (3)) is set equal tozero, this time with respect to the other variable IM, and an equationis obtained with respect to IM with the minimum error of adaptation tothe theoretical curve postulated for the cluster of points resultingfrom the experimental data:$\left. {{\left. {\frac{\partial ɛ}{\partial{IM}} = {2 \cdot {\sum\limits_{i = 1}^{n}\quad \left\{ {{{IB} \cdot \left( {1 - {10^{{- {IM}} \cdot N}i}} \right)} - W_{fi}} \right)}}} \right\} \cdot \left( {{IB} \cdot N_{i}} \right) \cdot 10^{{- {IM}} \cdot N}}i} \right) = 0$

[0054] With two possible solutions being obtained:

[0055] IB=0, a solution that can be ignored since it is absurd (patientwith sliming power=0),

[0056] and $\begin{matrix}{{IB} = \frac{\sum\limits_{i = 1}^{n}\quad {{W_{fi} \cdot N_{i} \cdot 10^{{- {IM}} \cdot N}}i}}{\sum\limits_{i = 1}^{n}\quad {{N_{i} \cdot \left( {1 - {10^{{- {IM}} \cdot N}i}} \right) \cdot 10^{{- {IM}} \cdot N}}i}}} & \left( {{Equation}\quad 5} \right)\end{matrix}$

[0057] Equating and simplifying the two Equations (4) and (5) (with twounknowns: IB and IM) and considering (for example) that the number ofpoints n is equal to 12 in total, one finally arrives at the followingequation which depends solely on IM: $\begin{matrix}{\frac{\sum\limits_{i = 1}^{n}\quad {{W_{fi} \cdot N_{i} \cdot 10^{{- {IM}} \cdot N}}i}}{{\sum\limits_{i = 1}^{n}\quad {{N_{i} \cdot 10^{{- {IM}} \cdot N}}i}} - {\sum\limits_{i = 1}^{n}\quad {{N_{i} \cdot 10^{{- 2}{{IM} \cdot N}}}i}}} = \frac{{\sum\limits_{i = 1}^{n}\quad W_{fi}} - {\sum\limits_{i = 1}^{n}\quad {{W_{fi} \cdot 10^{{- {IM}} \cdot N}}i}}}{12 - {2 \cdot {\sum\limits_{i = 1}^{n}\quad {10^{{- {IM}} \cdot N}{i \cdot 10^{{- 2}{{IM} \cdot N}}}i}}}}} & \left( {{Equation}\quad 6} \right)\end{matrix}$

[0058] This equation (which has to be solved by means of successiveiterations, preferably with the aid of computing means) enables one toobtain the value of IM (since this is the sole variable) for which theexponential curve fits as closely as possible to the initial cluster ofpoints.

[0059] Having obtained that value of IM from Equation (6), andsubstituting it into Equation (4), one also obtains the value of IBwhich, together with the value of IM stated earlier, completelydetermines the exponential curve for accumulated weight loss thatprovides the best mathematical model for the initial cluster of points.

[0060] As already mentioned, Equation (6) has to be solved with acomputer by means of a program specifically developed for that purpose.

[0061] In order to complete the solution, for each patient equation (6)has had to be solved more than a thousand times, including summations of12 products, by means of this program.

[0062] In order to solve the equation, one merely has to introduce(input) into the computer the weight losses of the patent accumulatedover 12 weeks of treatment and one obtains (output) the value of IB andthe value of IM for each patient and the sliming treatment that has beenfollowed.

[0063] In this way, a quick and easy method is obtained for comparingthe efficacy of different treatments and methods for slimming, as wellas for separating the different typologies of obese patients into groupsfor their consideration and later individual study.

[0064] The mathematical model developed enables an evaluation to be madequickly and effectively of the efficacy of any anti-obesity treatment,separating the efficacy of the treatment from the factors that dependexclusively on each individual, thereby being of great use when it comesdown on selecting among so many types of variations of treatment thathave had to be developed for arriving at the treatment that is claimedin this patent application.

[0065] Nevertheless, among thousands of patients, due to having a verywide range of values in the asymptote, the mean values of W_(fi) werenot very reliable due to the existence of a large scattering of valuesdepending on the asymptote resulting in each case. This led us toconfine ourselves solely, as a prior test, to all patients (about 3000)whose asymptote fell between +10% and −10% of the arithmetic mean of allthe patients studied (about 30,000 studies during the course of morethan 20 years ).

[0066] This mean asymptote (mean potential for weight loss among all thepatients) turned out to correspond to a value of weight loss W_(i) of17.78 kg. The arithmetic mean was used because, as the cluster of pointswas an asymmetric and positive distribution, the mean is higher than themedian and the mode.

[0067] Moreover, as the asymptote of many patients coincided, in orderto simplify things a study was made of their frequencies, applying thefollowing formula for obtaining the arithmetic mean:$\overset{\_}{x} = \frac{{n_{1} \cdot x_{1}} + {n_{2} \cdot x_{2}} + \ldots + {n_{n} \cdot x_{n}}}{n_{1} + n_{2} + \ldots + n_{n}}$

[0068] The band of ±10% of the mean value of the asymptote thereforestood at between 16 kg and 19.5 kg. A selection was made of 3000clinical records whose planning and expectations of weight loss(asymptote) fell between 16 and 19.56 kg, and the accumulated weeklyweight losses were noted during the course of 12 weeks, for eachpatient.

[0069] The arithmetic mean of the values obtained experimentally eachweek was then calculated, which permitted certain values of W_(fi) to beobtained which were used for obtaining IM and IB starting from Equations(6) and (4), respectively. The following values of W_(fi) were obtained:TABLE IV Arithmetic mean of the accumulated weight loss in each week forpatients within the band +/− 10% of the asymptote W_(f1) 2.75 W_(f2)5.74 W_(f3) 7.25 W_(f4) 9.30 W_(f5) 10.85 W_(f6) 12.22 W_(f7) 13.80W_(f8) 14.10 W_(f9) 14.75 W_(f10) 15.35 W_(f11) 15.75 W_(f12) 16.00

[0070] In the event of 12 weeks having passed and, having calculated thevalues of IM and IB, the weight loss was less than 16 kg, or higher than19.5 kg, then the specific results of that patient were discarded. So,this concerns the typical method in which the study methods areimplemented after having carried out the experiments and thecorresponding measurements and having obtained the specific data aposteriori.

[0071] Therefore, the mathematical-clinical study comprises threedifferent phases, namely:

[0072] In the first phase, the work band was centred by means of a meanasymptotic band and the corresponding W_(fi): with a single standardtreatment, the most frequent value of the asymptote, IB, was measured in3000 patients, thereby obtaining the mean asymptote (17.78 kg) and theasymptotic band in which the work would be carried out henceforth, justby finding the values of ±10% of the mean asymptote (between 16.00 kgand 17.78 kg). In the same way, during this work phase, the 12 meanvalues of W_(fi) were obtained for that asymptotic band (band of maximumweight losses weekly accumulated). Putting this another way: for an IBlying between 16.00 kg and 19.56 kg, it is assumed that if, from thatasymptotic band certain results are obtained, these will be perfectlyable to be extrapolated to other values of the asymptote. In otherwords: the best possible slimming method for IB=17.78 kg is also thebest method for any value of excess weight.

[0073] In the second phase, a selection is made of records of patientswhose mean prospects of weight loss lie within the chosen band, whichpermits the same values of W_(fi) to be used at all times, therebyminimising possible margins of error. In other words, applying first themethod of mean squares in order to obtain Equations (6) and (4), inorder to then confine oneself in this phase to a well defined asymptoticband that encompasses the mean asymptote.

[0074] In the third phase, the types of treatments and formulas arechosen that optimise the IM. In other words, a determination is made ofwhich types of treatments, formulas and doses of each component make ourtreatment the optimum one among all those possible. Of course, the stateof the art of each of the components of the formula is known separately(recommended dose or therapeutic windows), though without so far knowingwhich could be the optimum value of each of those components when mixedin the claimed formula. In this way, the standard treatments used in thedevelopment of the claimed formulation were those that really could bemore effective and innocuous (always less than the therapeutic window ofeach component for each of them).

[0075] In order to carry out the third phase, the types of treatment andslimming formulations are selected, that optimise the value of theefficacy index, based on various principles which are described infurther detail below, and among which the essential aspects are:

[0076] the importance of the ratio or principle of macro-micropeptiderelay of hypothalamus and hypophysis,

[0077] the ratio between the dose of hypothalamus and hypophysis, whichmust be approximately 1:100,

[0078] the ratio between the dose of hypophysis and thyroid, which mustbe approximately 1:3,

[0079] the dose of thyroid, which must not exceed 30 mg,

[0080] the dose of hypothalamus need not to exceed 0.2 mg,

[0081] the value of IB, which must be 17.78 kg (±10%), in other words,between 16 kg and 19.56 kg.

[0082] In order to optimise the model of the present invention, slimmingformulations were used which contained the essential componentshypophysis/hypothalamus/thyroids in the quantities shown below, withwhich formulations the values of IM shown in table V were obtained.TABLE V composition of the formulations hypothalamus hypophysis thyroidvalue of IM (×1/1000) 0.05 mg  5 mg 15 mg 7.87 0.05 mg  5 mg 30 mg 7.900.05 mg 10 mg 15 mg 8.02 0.05 mg 10 mg 30 mg 8.05 0.05 mg 20 mg 15 mg8.07 0.05 mg 20 mg 30 mg 8.14  0.1 mg  5 mg 15 mg 8.10  0.1 mg  5 mg 30mg 8.13  0.1 mg 10 mg 15 mg 8.12  0.1 mg 10 mg 30 mg 8.26  0.1 mg 20 mg15 mg 8.15  0.1 mg 20 mg 30 mg 8.18  0.2 mg  5 mg 15 mg 8.11  0.2 mg  5mg 30 mg 8.16  0.2 mg 10 mg 15 mg 8.03  0.2 mg 10 mg 30 mg 8.07  0.2 mg20 mg 15 mg 7.92  0.2 mg 20 mg 30 mg 7.99

[0083] For all the combinations of the essential components of theformulation, good values were obtained for IM, the best of them—IM-8.26—being obtained with the formulation containing 0.1 mg ofhypothalamus, 10 mg of hypophysis and 30 mg of thyroid.

[0084] It has been possible to conclude that the value of the constantIM —the efficacy index—is essential for the preparation of a slimmingformulation.

[0085] In this way, the system and procedure of the present inventionprovide a useful tool for comparing the efficacy of different slimmingtreatments, as well as for separating the different types of obesepatient, in such a way that an individual study can then be conducted.

[0086] The third objective of the present invention is therefore aformulation whose essential components and the quantities in which theyare present have been obtained as a result of the application of theprocedure described above.

[0087] From the study of 30000 patients and the application of thedescribed procedure, the formulation of the present invention has beenarrived at, based on the values of IM obtained and founded on a seriesof principles that are described below:

[0088] 1. Principle of neuro-endocrine balance, or principle of relayaction of the hypothalamic-hypophyseal axis. The basis of this principlelies in the fact that the information in the encephalon is effected bymeans of neurotransmitters at the neurone synapse level. Theseneurotransmitters are generally micropeptides. There exists a reserve ofthose micropeptides, on which the hypothalamus also feeds, in such a waythat the hypothalamus captures them in order to synthesise hypothalamicreleasing factors and which act as messengers for controlling hormonesynthesis in the hypophysis (macropeptide hormones).

[0089] In the formulation according to the present invention, veryspecial consideration is given to the molecular weights of the releasingfactors of the hypothalamus and the molecular weights of the hormones ofthe anterior lobe of the hypophysis. The necessary quantity ofhypothalamus powder in the formulation, and of hypophysis powder,calculated according to the results of the procedure described above andbearing in mind the present principle of endocrine balance, lies between0.01 mg and 0.5 mg for hypothalamus powder, and 1 mg to 30 mg forhypophysis powder. By means of applying the procedure object of thepresent invention, one arrives at the preferred quantity of hypothalamuspowder compared to hypophysis powder, which must be 0.1 mg forhypothalamus powder and 10 mg for hypophysis powder. Therefore, theseare the quantities in which these two basic components of theformulation of the present invention will preferably be present.

[0090] So, according to the principle of the relay effect of thehypothalamic-hypophyseal axis, and according to the principle of naturalsatiation of appetite, the formulation of the present invention containshypothalamus powder and hypophysis powder. The proportions in which theyare present have been calculated according to the mean molecular weightsand the primary and secondary structures of the hypothalamic releasingfactors, along with the molecular weights and structures of the hormonesof the glandular hypophysis, as well as considering the results of theapplication of the system and procedure of the present invention.

[0091] 2. Principle of interglandular balance. The endocrine cascade isconsidered as a system integrated and interrelated by means ofbio-feedback mechanisms. It is not possible to treat obesity solely bymeans of thyroxine or thyroid extracts, owing to the close interrelationthat the glandular secretion mechanisms have. Serious endocrinemaladjustments can occur with blockage of the secretion of hypophysealTSH and even generalised blockages of the hypophysis, which can causedysfunctions in other glands such as the pancreas, the suprarenals orthe gonads, with the consequent problems of health and pathologies atthe levels of those glands. By virtue of this interrelation,contributions of extract of a single gland cannot be supplied withoutsupplying contributions of the others. Nevertheless, account must betaken of the way in which proteins are absorbed via the intestinaltract, which is not amino acid to amino acid but instead by means ofpassage via the digestive barrier of real polypeptide microchains.

[0092] Nor is it a question of using the same quantity of eachopotherapic extract, since not all hormones or hypothalamic releasingfactors have the same molecular weight nor the same primary andsecondary structure.

[0093] Bearing in mind the complex intestinal absorption of peptides, aswell as the major differences in primary and secondary structure ofhormones and of releasing factors, with the application of the procedureof the present invention it has been possible to transfer the resultsobtained for each patient with different mixtures and, by means ofsuccessive practical trials, adjust the quantities according to theresults of the procedure. In other words, the interglandular balance hasbeen achieved by means of the method of successive trials, in which thereal quantities of opotherapic extracts that must be present in theformulation have been adjusted.

[0094] Other essential components of the formulation of the presentinvention, according to the described principle of endocrine systemintegrated and interrelated by means of bio-feedback mechanisms, are:

[0095] thyroid powder

[0096] suprarenal cortex powder and

[0097] pancreas powder.

[0098] The quantities in which these components are present in theformulation of the present invention are calculated according to thequantity of hypophysis powder, as stated above, and bearing in mind thecharacteristics of the hormone segregated by each gland.

[0099] The formulation of the present invention can also contain gonadpowder, in other words testicle powder (in men) or ovary powder (inwomen).

[0100] 3 The principle of synergy with dispersion of secondary effects.The quantity of drugs present in the formulation of the presentinvention lies below the therapeutic limits. As is known, in thetreatment of illnesses with various drugs, these act with their mainaction on the problem and producing side effects (some are metabolisedby the liver, others by the kidneys, others by the intestines, etc.),which have an effect on different organs, thereby the undesired effectis minimised and the objective of curing the illness is strengthened bysynergy. Therefore, the synergy of multiple therapeutic agents in thecase of treating obesity must not be ignored. Some of the factorsinfluencing obesity are sedentarism, liquid retention, constipation,excess ingestion, glandular imbalance, stress. The diagram shown in FIG.5 shows these factors that influence obesity and their relation with thecomponents of the formulation of the present invention which act againstthe negative effects produced by those factors.

[0101] According to the basic diagram shown, it will be necessary toincrease or decrease the quantity of one or more of the components ofthe formulation in the dose depending on the stated aetiologicalfactors.

[0102] All these components mentioned in the diagram, such as anopotherapic product, a plant extract, a laxative, an anorexic, etc., arefairly different from each other and have very different side effects,though their main action is directed towards treatment of obesity.

[0103] Among the components of a formulation according to the presentinvention, diuretics can be present, which are very necessary at thestart of a slimming treatment. These will preferably be present in theformulation in very low quantities. In the case of women they are alsouseful on premenstrual days since, although the body retains liquidsprior to menstruation and tends to eliminate them afterwards, the amountretained on premenstrual days is appreciably greater than the amounteliminated after menstruation. In some cases, with a lot of sedentarism,this difference can be a real cause of obesity since the liquidsaccumulated in the tissues open up gaps with are exploited by adipocytesin order to become hypertrophied.

[0104] Diet can also be used as a therapeutic agent against obesity, andwill be practised in a moderate way in “small doses”. This meanseliminating bread, sweets, alcohol, and ingesting smaller quantities ofother foods, though without measuring.

[0105] 4. Principle of homeomorphia and homeobaria. This principle, onwhich the formulation of the present invention also rests, is based onthe hypothalamic control over body shape and weight. At the start ofrecording their excess weight, some patients observe a deformation ofthe body. This fact is not surprising if it is related to the exhaustionof the reserve of neurotransmitters due to excessive stress. It has beenstated earlier that when the hypothalamus cannot properly capture theneurotransmitters it needs from the encephalic reserve, then it startsto function badly. Just as there exist homeostatic nuclei of hunger,satiation, hyperthermia, hypoglucemia, etc., so there can also exist inthe hypothalamus control nuclei over body shape, in order to achieve anenergy homeostasia of the entropic type or with regard to tissue. Theexistence can therefore be postulated of a homeomorphia in charge ofcontrolling the hypothalamus and if the stated nuclei exist, then ahomeobaria could also occur which is also dependent on the control ofthe hypothalamus.

[0106] It is known that the hypothalamus receives signals coming fromalmost all possible sources of the central nervous system, and when aperson suffers pain, part of the pain signal is transmitted to thehypothalamus. In the same way, when a person has exciting or depressingideas, part of the signals are transmitted to the hypothalamus. It hasbeen confirmed that the hypothalamus is a meeting point for informationrelated to the well-being of the body.

[0107] 5. Principle of hypothalamic satiation of appetite. Theformulation of the present invention is also based on the acknowledgedfact that satiation of appetite is governed by the ventromedial nucleiof the hypothalamus, and that the sensation of hunger derives from itsventrolateral nuclei. It is also known that considerable weightincreases sometimes occur as a consequence of psychological traumas. Thehypothalamus therefore receives information from the nerve centres wherethe suffering due to these traumas is being processed.

[0108] In the preparation of opotherapic products, moreover, thehypothalamus powder used does not contain material from theventrolateral regions, which are eliminated from the hypothalamuses ofanimals before being crushed, purified and dried. Therefore, thishypothalamus powder only contains material from the ventromedial nucleiand, being present in a formulation for a slimming treatment, theystimulate the hypothalamic nuclei for satiation in natural way. In theformulation of the present invention, the hypothalamus powder is presentin small quantities, so that no side effects of hyperexcitation,arterial hypertension or others take place.

[0109] 6. Principle of balanced elimination. The aim is to aid diuresisand defecation. Retention of liquids in some parts of the body andintestinal constipation are factors that must be borne in mind in alltreatments of obesity. There exist many diuretic plant species, such asArenaria rubra or Equisetum arvense. Nevertheless, in serious situationsof liquid retention even using both simultaneously does not give goodresults. These cases occur when the kidneys are “lazy kidneys”. It isthen more advisable to use a diuretic in very small quantities.

[0110] Optionally, therefore, the formulation of the present inventioncan include some drugs and plants intended to facilitate duringtreatment the elimination of retained liquids—increasing thediuresis—and also faecal elimination, avoiding intestinal constipation.Bumetanide is preferably used as a very reliable diuretic in prolongedtreatments at very low doses.

[0111] Similarly, the plants used in an optional way accelerate thedigestion and intestinal transit. As far as intestinal constipation isconcerned, use can be made of a medicinal plant such as Rhamnuspursiana, or cascara sagrada, as a laxative, and in some especiallycomplicated cases, an infusion of Cassia angustifolia. The quantity ofRhamnus pursiana present in the formulation is preferably between 15 and20 mg.

[0112] As a digestive tonic or accelerator of digestion, use isoptionally and preferably made of a nebulised extract of Fumariaofficinalis. The amount of Fumaria officinalis in the formulation isbetween 50 and 70 mg.

[0113] The formulation of the present invention can also include somemineral vitamin complex because, according to the principle of synergyof multiple agents at very low doses and with dispersion of sideeffects, a moderate diet is included in the treatment and thereforebread, alcohol, sweets, pizzas and nuts are categorically banned.

[0114] The formulation of the present invention can also include,according to the described principle of homeomorphia and homeobaria,very low doses of benzodiazepines in order to eliminate residualmuscular tension, both of smooth fibre and of striated fibre. Thesebenzodiazepines are preferably chlorodiazepoxide for smooth fibre anddiazepam for striated fibre. No type of cross-reaction has been observedof the pharmacological agents used, neither of simple type nor of therecombined type.

[0115] The formulation of the present invention can also include ananorexic, according to the principle of reduction of appetite, both innatural form by means of hypothalamus powder and in pharmacologicalform. When administered in pharmacological form, this anorexic ispreferably diethylpropion (anfepramone or fluoxetine in a quantitybetween 10 and 20 mg).

[0116] Therefore, the formulation according to the present inventioncomprises at least:

[0117] hypothalamus powder in a quantity between 0.01 and 0.5 mg,

[0118] hypophysis powder in a quantity between 1 and 30 mg,

[0119] thyroid powder in a quantity between 10 and 40 mg,

[0120] suprarenal cortex powder and pancreas powder in a proportion of1:4.

[0121] According to an alternative embodiment, a formulation comprisesat least:

[0122] hypothalamus powder in a quantity between 0.01 and 0.5 mg,

[0123] hypophysis powder in a quantity between 1 and 30 mg,

[0124] thyroid powder in a quantity between 10 and 40 mg,

[0125] suprarenal cortex powder and pancreas powder in a proportion of1:4

[0126] a laxative and

[0127] a digestive tonic.

[0128] The laxative and the digestive tonic can be present in theformulation as plant extracts in a total quantity between 70 mg and 90mg.

[0129] The plant extracts are preferably:

[0130]Fumaria officinalis as a digestive tonic, which is present in aquantity between 50 and 70 mg.

[0131]Rhamnus pursiana as a laxative in a quantity between 15 and 20 mg.

[0132] According to an additional alternative embodiment, a formulationcomprises at least:

[0133] hypothalamus powder in a quantity between 0.01 and 0.5 mg,

[0134] hypophysis powder in a quantity between 1 and 30 mg,

[0135] thyroid powder in a quantity between 10 and 40 mg,

[0136] suprarenal cortex powder and pancreas powder in a proportion of1:4

[0137] a laxative,

[0138] a digestive tonic and

[0139] at least one muscle relaxant.

[0140] In the formulation of the present invention, the muscle relaxantis preferably selected from between:

[0141] diazepam as striated fibre relaxant, in a quantity between 1.0and 2.5 mg,

[0142] chlorodiazepoxide as smooth fibre relaxant, in a quantity between1.0 and 2.5 mg, and

[0143] a mixture of both.

[0144] According to an additional alternative embodiment, a formulationcomprises at least:

[0145] hypothalamus powder in a quantity between 0.01 and 0.5 mg,

[0146] hypophysis powder in a quantity between 1 and 30 mg,

[0147] thyroid powder in a quantity between 10 and 40 mg,

[0148] suprarenal cortex powder and pancreas powder in a proportion of1:4

[0149] plant extracts,

[0150] at least one muscle relaxant, and

[0151] a diuretic

[0152] The diuretic is preferably present in a quantity between 0.2 and0.5 mg.

[0153] The diuretic is preferably bumetanide and is present in aquantity between 0.2 and 0.5 mg.

[0154] An additional alternative embodiment refers to a formulationwhich includes at least:

[0155] hypothalamus powder in a quantity between 0.01 and 0.5 mg,

[0156] hypophysis powder in a quantity between 1 and 30 mg,

[0157] thyroid powder in a quantity between 10 and 40 mg,

[0158] suprarenal cortex powder and pancreas powder in a proportion of1:4

[0159] plant extracts in a quantity between 70 mg and 90 mg,

[0160] a diuretic in a quantity between 0.2 and 0.5 mg,

[0161] at least one muscle relaxant, and

[0162] potassium bicarbonate in a quantity between 100 and 140 mg.

[0163] According to a preferred embodiment, a formulation comprises atleast:

[0164] hypothalamus powder in a quantity of 0.01 mg,

[0165] hypophysis powder in a quantity of 10 mg,

[0166] thyroid powder in a quantity of 30 mg, and

[0167] suprarenal cortex powder and pancreas powder in a proportion of1:4.

[0168] A second preferred alternative embodiment refers to a formulationwhich comprises:

[0169] hypothalamus powder in a quantity of 0.01 mg,

[0170] hypophysis powder in a quantity of 10 mg,

[0171] thyroid powder in a quantity of 30 mg,

[0172] suprarenal cortex powder in a quantity of 20 mg,

[0173] pancreas powder in a quantity of 80 mg

[0174]Fumaria officinalis as a digestive tonic in a quantity between 50and 70 mg,

[0175]Rhamnus pursiana as a laxative in a quantity between 15 and 20 mg,

[0176] diazepam in a quantity between 1.0 and 2.5 mg,

[0177] chlorodiazepoxide in a quantity between 1.0 and 2.5 mg,

[0178] bumetanide in a quantity between 0.2 and 0.5 mg, and

[0179] potassium bicarbonate in a quantity between 100 and 140 mg.

[0180] Moreover, the formulation of the present invention can include inany of its embodiments and as an option an anorexic in a quantitybetween 10 and 30 mg. This anorexic can be anfrepramone, preferably in aquantity between 20 and 30 mg or fluoxetine in a quantity between 10 and20 mg.

[0181] The present invention also refers to a galenic form for the oraladministration of a formulation as has been defined above, whichincludes at least:

[0182] hypothalamus powder in a quantity between 0.01 and 0.5 mg,

[0183] hypophysis powder in a quantity between 1 and 30 mg,

[0184] thyroid powder in a quantity between 10 and 40 mg,

[0185] suprarenal cortex powder and pancreas powder in a proportion of1:4

[0186] This galenic form is preferably selected from among capsules,tablets, pills and pastilles.

[0187] In a preferred embodiment a galenic form for the administrationof a formulation comprises at least:

[0188] hypothalamus powder in a quantity of 0.01 mg,

[0189] hypophysis powder in a quantity of 10 mg,

[0190] thyroid powder in a quantity of 30 mg,

[0191] suprarenal cortex powder in a quantity of 20 mg,

[0192] pancreas powder in a quantity of 80 mg

[0193]Fumaria officinalis as a digestive tonic in a quantity between 50and 70 mg,

[0194]Rhamnus pursiana as a laxative in a quantity between 15 and 20 mg,

[0195] diazepam in a quantity between 1.0 and 2.5 mg,

[0196] chlorodiazepoxide in a quantity between 1.0 and 2.5 mg,

[0197] bumetanide in a quantity between 0.2 and 0.5 mg, and

[0198] potassium bicarbonate in a quantity between 100 and 140 mg.

[0199] In an even more preferred embodiment a galenic form for theadministration of a formulation comprises:

[0200] capsules of a first type (format 2) which contain:

[0201] hypothalamus powder in a quantity of 0.01 mg,

[0202] thyroid powder in a quantity of 30 mg,

[0203] diazepam in a quantity between 1.0 and 2.5 mg,

[0204] chlorodiazepoxide in a quantity between 1.0 and 2.5 mg,

[0205] bumetanide in a quantity between 0.2 and 0.5 mg, and

[0206] capsules of a second type (format 1) which contain:

[0207] hypophysis powder in a quantity of 10 mg,

[0208] suprarenal cortex powder in a quantity of 20 mg,

[0209] pancreas powder in a quantity of 80 mg

[0210]Rhamnus pursiana as a laxative in a quantity between 15 and 20 mg,

[0211]Fumaria officinalis as a digestive tonic in a quantity between 50and 70 mg, and

[0212] potassium bicarbonate in a quantity between 100 and 140 mg.

[0213] A galenic form for the administration of a formulation preferablycomprises:

[0214] capsules of a first type (format 2) which contain:

[0215] hypothalamus powder in a quantity of 0.1 mg,

[0216] thyroid powder in a quantity of 30 mg,

[0217] diazepam in a quantity of 1.5 mg,

[0218] chlorodiazepoxide in a quantity of 1.5 mg, and

[0219] bumetanide in a quantity of 0.3 mg, and

[0220] capsules of a second type (format 1) which contain:

[0221] hypophysis powder in a quantity of 10 mg,

[0222] suprarenal cortex powder in a quantity of 20 mg,

[0223] pancreas powder in a quantity of 80 mg

[0224]Rhamnus pursiana and Fumaria officinalis in a total quantity of 80mg, and

[0225] potassium bicarbonate in a quantity of 100 mg.

[0226] The formulation of the present invention will preferably be takentwice a day, always between meals. It will preferably be taken two hoursbefore the main meal and two or three hours before dinner. It is takenwith a fair amount of water in order to accelerate the gastric transitwhich, due to being acid, greatly alters the animal and plant extracts,and so that the formulation reaches the alkaline intestinal tract asquickly as possible.

[0227] The present formulation presents the following advantages withrespect to other formulations of the state of the art:

[0228] no adverse reactions have ever been observed, on account of thesmall doses of each component;

[0229] not just a slimming effect is obtained but also euphoria andwell-being are observed, alleviation of allergy problems, alleviation ofrheumatological problems, alleviation of menstrual problems, alleviationof digestive problems, alleviation of sleeping problems, drop incholesterol, triglycerides and uric acid, alleviation of skin problemsand correction of arterial hypertension.

[0230] Some of these advantages derive from the actual effect of losingweight and others are predictable effects of the formulation itself.

EXAMPLES Example 1

[0231] By the usual methods known in the art, a formulation is preparedcomprising:

[0232] 0.01 mg of hypothalamus powder,

[0233] 10 mg of hypophysis powder,

[0234] 30 mg of thyroid powder,

[0235] 20 mg of suprarenal cortex powder,

[0236] 80 mg of pancreas powder,

[0237] 15 mg of testicle powder,

[0238] 65 mg of Fumaria officinalis,

[0239] 17 mg of Rhamnus pursiana,

[0240] 1.5 mg of diazepam,

[0241] 1.5 mg of chlorodiazepoxide,

[0242] 0.3 mg of bumetanide, and

[0243] 100 mg of potassium bicarbonate,

Example 2

[0244] By the usual methods known in the art, a formulation similar tothat of example 1 is prepared, but with 15 mg of ovary powder instead of15 mg of testicle powder:

Example 3

[0245] By the usual methods known in the art, a galenic form is preparedcomprising:

[0246] capsules of format 2 which contain:

[0247] hypothalamus powder in a quantity of 0.1 mg,

[0248] thyroid powder in a quantity of 30 mg,

[0249] diazepam in a quantity of 1.5 mg,

[0250] chlorodiazepoxide in a quantity of 1.5 mg, and

[0251] bumetanide in a quantity of 0.3 mg, and

[0252] capsules of format 1 which contain:

[0253] hypophysis powder in a quantity of 10 mg,

[0254] suprarenal cortex powder in a quantity of 20 mg,

[0255] pancreas powder in a quantity of 80 mg

[0256] 65 mg of Fumaria officinalis,

[0257] 17 mg of Rhamnus pursiana, and

[0258] 100 mg of potassium bicarbonate.

1. A formulation for a slimming treatment comprising at least:hypothalamus powder in a quantity between 0.01 and 0.5 mg, hypophysispowder in a quantity between 1 and 30 mg, thyroid powder in a quantitybetween 10 and 40 mg, suprarenal cortex powder and pancreas powder in aproportion of 1:4.
 2. A formulation according to claim 1, whichcomprises at least: hypothalamus powder in a quantity between 0.01 and0.5 mg, hypophysis powder in a quantity between 1 and 30 mg, thyroidpowder in a quantity between 10 and 40 mg, suprarenal cortex powder andpancreas powder in a proportion of 1:4 a laxative and a digestive tonic.3. A formulation according to claim 2 wherein the laxative and thedigestive tonic are present in the formulation as plant extracts in atotal quantity between 70 mg and 90 mg.
 4. A formulation according toclaim 2 wherein the laxative and the digestive tonic are: Fumariaofficinalis as a digestive tonic, present in the formulation in aquantity between 50 and 70 mg, and Rhamnus pursiana as a laxative,present in the formulation in a quantity between 15 and 20 mg.
 5. Aformulation according to claim 1, which comprises at least: hypothalamuspowder in a quantity between 0.01 and 0.5 mg, hypophysis powder in aquantity between 1 and 30 mg, thyroid powder in a quantity between 10and 40 mg, suprarenal cortex powder and pancreas powder in a proportionof 1:4 a laxative, a digestive tonic and at least one muscle relaxant.6. A formulation according to claim 5 wherein the muscle relaxant isselected from between: diazepam, present in the formulation in aquantity between 1.0 and 2.5 mg, chlorodiazepoxide, present in theformulation in a quantity between 1.0 and 2.5 mg, and a mixture of both.7. A formulation according to claim 1, comprising at least: hypothalamuspowder in a quantity between 0.01 and 0.5 mg, hypophysis powder in aquantity between 1 and 30 mg, thyroid powder in a quantity between 10and 40 mg, suprarenal cortex powder and pancreas powder in a proportionof 1:4 a laxative a digestive tonic, at least one muscle relaxant, and adiuretic
 8. A formulation according to claim 7 wherein the diuretic isbumetanide and is present in the formulation in a quantity between 0.2and 0.5 mg.
 9. A formulation according to claim 1, comprising at least:hypothalamus powder in a quantity between 0.01 and 0.5 mg, hypophysispowder in a quantity between 1 and 30 mg, thyroid powder in a quantitybetween 10 and 40 mg, suprarenal cortex powder and pancreas powder in aproportion of 1:4, a laxative, a digestive tonic, at least one musclerelaxant, a diuretic in a quantity between 0.2 and 0.5 mg, potassiumbicarbonate in a quantity between 100 and 140 mg.
 10. A formulationaccording to claim 1, comprising at least: hypothalamus powder in aquantity of 0.01 mg, hypophysis powder in a quantity of 10 mg, thyroidpowder in a quantity of 30 mg, and suprarenal cortex powder and pancreaspowder in a proportion of 1:4.
 11. A formulation according to claim 10,comprising at least: hypothalamus powder in a quantity of 0.01 mg,hypophysis powder in a quantity of 10 mg, thyroid powder in a quantityof 30 mg, suprarenal cortex powder in a quantity of 20 mg, pancreaspowder in a quantity of 80 mg Fumaria officinalis as a digestive tonicin a quantity between 50 and 70 mg, Rhamnus pursiana as a laxative in aquantity between 15 and 20 mg, diazepam in a quantity between 1.0 and2.5 mg, chlorodiazepoxide in a quantity between 1.0 and 2.5 mg,bumetanide in a quantity between 0.2 and 0.5 mg, and potassiumbicarbonate in a quantity between 100 and 140 mg.
 12. A formulationaccording to claim 1, which also comprises an extract selected frombetween ovary extract and testicle extract.
 13. A formulation accordingto claim 12, wherein the ovary extract or testicle extract is present inthe formulation in a quantity between 15 and 20 mg.
 14. A formulationaccording to claim 1, comprising at least: hypothalamus powder in aquantity between 0.01 and 0.5 mg, hypophysis powder in a quantitybetween 1 and 30 mg, thyroid powder in a quantity between 10 and 40 mg,suprarenal cortex powder and pancreas powder in a proportion of 1:4 ananorexic in a quantity between 10 and 30 mg.
 15. A formulation accordingto claim 14, wherein the anorexic is anfepramone and is present in theformulation in a quantity between 20 and 30 mg.
 16. A formulationaccording to claim 14, wherein the anorexic is fluoxetine and is presentin the formulation in a quantity between 10 and 20 mg.
 17. A galenicform for the administration of a formulation comprising at least:hypothalamus powder in a quantity between 0.01 and 0.5 mg, hypophysispowder in a quantity between 1 and 30 mg, thyroid powder in a quantitybetween 10 and 40 mg, suprarenal cortex powder and pancreas powder in aproportion of 1:4 as defined in claim 1, said galenic form being adaptedfor oral administration.
 18. A galenic form according to claim 17, whichis selected from among capsules, tablets, pills and pastilles.
 19. Agalenic form according to claim 17, for the administration of aformulation which comprises at least: hypothalamus powder in a quantityof 0.01 mg, hypophysis powder in a quantity of 10 mg, thyroid powder ina quantity of 30 mg, suprarenal cortex powder in a quantity of 20 mg,pancreas powder in a quantity of 80 mg Fumaria officinalis as adigestive tonic in a quantity between 50 and 70 mg, Rhamnus pursiana asa laxative in a quantity between 15 and 20 mg, diazepam in a quantitybetween 1.0 and 2.5 mg, chlorodiazepoxide in a quantity between 1.0 and2.5 mg, bumetanide in a quantity between 0.2 and 0.5 mg, and potassiumbicarbonate in a quantity between 100 and 140 mg.
 20. A galenic formaccording to claim 17, for the administration of a formulation whichcomprises: capsules of a first type which contain: hypothalamus powderin a quantity of 0.01 mg, thyroid powder in a quantity of 30 mg,diazepam in a quantity between 1.0 and 2.5 mg, chlorodiazepoxide in aquantity between 1.0 and 2.5 mg, bumetanide in a quantity between 0.2and 0.5 mg, and capsules of a second type which contain: hypophysispowder in a quantity of 10 mg, suprarenal cortex powder in a quantity of20 mg, pancreas powder in a quantity of 80 mg Rhamnus pursiana as alaxative in a quantity between 15 and 20 mg, Fumaria officinalis as adigestive tonic in a quantity between 50 and 70 mg, and potassiumbicarbonate in a quantity between 100 and 140 mg.
 21. A galenic form forthe administration of a formulation according to claim 19, whichcomprises: capsules of a first type which contain: hypothalamus powderin a quantity of 0.1 mg, chlorodiazepoxide in a quantity between 1.0 and2.5 mg, and thyroid powder in a quantity of 30 mg, diazepam in aquantity of 1.5 mg, chlorodiazepoxide in a quantity of 1.5 mg, andbumetanide in a quantity of 0.3 mg, and capsules of a second type whichcontain: hypophysis powder in a quantity of 10 mg, suprarenal cortexpowder in a quantity of 20 mg, pancreas powder in a quantity of 80 mgRhamnus pursiana and Fumaria officinalis in a total quantity of 80 mg,and potassium bicarbonate in a quantity of 100 mg.